Abiraterone acetate-containing preparations

Small tablets with high abiraterone acetate content, using aminoalkyl methacrylate copolymer E as a binder, address the challenges of size and dissolution rate issues in existing formulations, ensuring effective and easy administration.

JP7581712B2Active Publication Date: 2024-11-13NIPRO CORP
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2020148552
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-09-03
Publication Date
2024-11-13
Estimated Expiration
2040-09-03

AI Technical Summary

Technical Problem

Existing abiraterone acetate tablets for treating castration-resistant prostate cancer are large, difficult to administer, and exhibit decreased dissolution rates over time due to long-term storage, affecting patient compliance and efficacy.

Method used

Formulating small tablets with a high content of abiraterone acetate using granules containing aminoalkyl methacrylate copolymer E as a binder, along with a disintegrant, to maintain good dissolution characteristics even after long-term storage.

Benefits of technology

The formulation provides small tablets with a high abiraterone acetate content, improving ease of administration and maintaining dissolution properties over time, enhancing patient compliance and treatment efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007581712000004
    Figure 0007581712000004
  • Figure 0007581712000005
    Figure 0007581712000005
  • Figure 0007581712000006
    Figure 0007581712000006
Patent Text Reader

Abstract

To provide a small tablet having a higher content of abiraterone acetate to improve ingestibility and showing good elution characteristics even after long-term storage.SOLUTION: A tablet comprises: a granulated product comprising abiraterone acetate as an active ingredient in an amount of 55 to 95% by mass based on a total mass of the tablet; a disintegrant; and an aminoalkyl methacrylate copolymer E. An agglomerated material comprises: abiraterone acetate as an active ingredient in the amount of 55 to 95% by mass based on the total mass of the tablet; a disintegrant that is at least one kind selected from a group consisting of croscarmellose sodium, crospovidone, low degree of substitution hydroxypropyl cellulose, and partially pregelatinized starch; and an aminoalkyl methacrylate copolymer E.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a tablet containing abiraterone acetate, and more particularly to an abiraterone acetate-containing mini-tablet having an increased content of abiraterone acetate. [Background technology]

[0002] Abiraterone acetate has the following formula: [ka] It is rapidly hydrolyzed to abiraterone in vivo and inhibits the activity of 17α-hydroxylase / C17,20-lyase (CYP17), an androgen synthesis enzyme. It reduces the content of testosterone and dihydrotestosterone in testicular, adrenal and prostatic tumor tissues, such as castration-resistant prostate cancer, and suppresses tumor growth. Tablets containing abiraterone acetate as an active ingredient are sold under names such as "Zytiga (registered trademark) Tablets 250 mg" as a treatment for castration-resistant prostate cancer (Non-Patent Document 1).

[0003] When abiraterone acetate is used as an active ingredient in a castration-resistant prostate cancer treatment, it is usually administered orally to adults in combination with prednisolone at a dose of 1,000 mg once a day on an empty stomach, and currently, as mentioned above, tablets containing 250 mg of abiraterone acetate per tablet are used, and four tablets are taken per day. This tablet contains a low amount of abiraterone acetate, about 35% by mass, and is a large tablet with a major axis of 16 mm, a minor axis of 9.6 mm, a thickness of 6.3 mm, and a total mass of 736 mg.

[0004] Abiraterone acetate is a poorly soluble drug with low oral availability, so in order to increase the dissolution rate of the drug, it has been disclosed that nanoparticles of abiraterone acetate obtained by grinding abiraterone acetate together with a specific grinding compound or enhancer are used (Patent Document 1). Furthermore, the content of abiraterone acetate in the tablet specifically described in Patent Document 1 is about 15% by mass, which is even lower than that of commercially available tablets, and there is no discussion whatsoever about the content of the active ingredient or the size of the tablet. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] JP 2018-135351 A [Non-patent literature]

[0006] [Non-Patent Document 1] "Zytiga (registered trademark) Tablets 250 mg" package insert Summary of the Invention [Problem to be solved by the invention]

[0007] However, as described above, the tablets described in Non-Patent Document 1 are large in size, which makes them difficult to take, and since four tablets must be taken per day, it is difficult to obtain patient compliance.

[0008] Furthermore, the inventors' research has revealed that by using a granule containing a binder together with the active ingredient abiraterone acetate, it is possible to provide small tablets with a high content of abiraterone acetate and good dissolution properties, and a previous application was filed (Patent Application No. 2019-199132). However, it has been found that these formulations have a problem in that the dissolution rate tends to decrease over time when stored for a long period of time.

[0009] Therefore, an object of the present invention is to provide a small tablet having a higher content of abiraterone acetate in order to improve ease of administration, and which exhibits good dissolution characteristics even after long-term storage. [Means for solving the problem]

[0010] As a result of investigating the above problems, the inventors have found that by using a granule containing aminoalkyl methacrylate copolymer E as a binder together with abiraterone acetate as the active ingredient, it is possible to provide small tablets with a high content of abiraterone acetate that have good dissolution properties even after long-term storage, and have completed the present invention.

[0011] That is, the present invention provides [1] A tablet comprising a granule containing 55 to 95% by mass of abiraterone acetate as an active ingredient relative to the total mass of the tablet, a disintegrant, and aminoalkyl methacrylate copolymer E. [2] The tablet according to the above [1], wherein the total mass of the tablet is 420 mg or less. [3] The tablet according to the above [1] or [2], wherein the tablet contains 65 to 95% by mass of abiraterone acetate based on the total mass of the tablet. [4] The tablet according to any one of the above [1] to [3], wherein the disintegrant is at least one selected from the group consisting of croscarmellose sodium, crospovidone, low-substituted hydroxypropyl cellulose, and partially pregelatinized starch; and [5] The tablet according to any one of the above [1] to [4], further comprising another binder. Regarding. Effect of the Invention

[0012] According to the present invention, by using a granule containing aminoalkyl methacrylate copolymer E as a binder, together with the active ingredient abiraterone acetate, and a disintegrant, it is possible to provide a small tablet with a high content of abiraterone acetate, which has good dissolution properties even after long-term storage and contains 55 to 95% by mass of the active ingredient abiraterone acetate relative to the mass of the entire tablet, thereby improving the ease of administration to patients. [Brief description of the drawings]

[0013] [Figure 1] 1 is a graph showing the dissolution rate (%) of abiraterone acetate in Example 1. [Diagram 2] 1 is a graph showing the dissolution rate (%) of abiraterone acetate in Comparative Example 1. [Diagram 3] 1 is a graph showing the dissolution rate (%) of abiraterone acetate in Example 2. [Figure 4] 1 is a graph showing the dissolution rate (%) of abiraterone acetate in Comparative Example 2. [Diagram 5] 1 is a graph showing the dissolution rate (%) of abiraterone acetate in Example 3. [Figure 6] 1 is a graph showing the dissolution rate (%) of abiraterone acetate in Example 4. [Figure 7] 1 is a graph showing the dissolution rate (%) of abiraterone acetate in Example 5. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] The tablet of the present invention contains a granulation product containing 55-95% by mass of abiraterone acetate as an active ingredient based on the total mass of the tablet, a disintegrant, and aminoalkyl methacrylate copolymer E. By using aminoalkyl methacrylate copolymer E as a binder, a very good granulation product can be obtained. Aminoalkyl methacrylate copolymer E is hydrophobic but dissolves in acidic conditions. Even if the disintegrating power of a disintegrant or the like decreases under temperature and humidity conditions such as 60°C and 75% humidity, the aminoalkyl methacrylate copolymer E itself dissolves in the first fluid (pH 1.2) of the Japanese Pharmacopoeia dissolution test, so that water is drawn into the tablet, and the disintegration and dissolution properties of the tablet are thought to be maintained.

[0015] The content of abiraterone acetate in the tablet is 55% by mass or more, preferably 65% ​​by mass or more, more preferably 75% by mass or more, based on the total mass of the tablet. If the content of abiraterone acetate is less than 55% by mass based on the total mass of the tablet, the tablet cannot be sufficiently miniaturized, and it tends to be difficult to improve the ease of administration. In addition, the content of abiraterone acetate in the tablet is 95% by mass or less, preferably 90% by mass or less, based on the total mass of the tablet. If the content of abiraterone acetate is more than 95% by mass based on the total mass of the tablet, the content of the binder is relatively reduced, and the dissolution tends to be reduced.

[0016] From the viewpoint of ease of administration, the tablet of the present invention preferably has a total mass of 420 mg or less, more preferably 260 to 420 mg.

[0017] Aminoalkyl methacrylate copolymer E is known as EUDRAGIT (registered trademark) E 100 (manufactured by Evonik) and EUDRAGIT (registered trademark) E PO (manufactured by Evonik). The content of aminoalkyl methacrylate copolymer E in the tablet is not particularly limited, but is usually preferably 0.01% by mass or more, more preferably 0.1% by mass or more. The content of binder in the tablet is usually preferably 20% by mass or less, more preferably 10% by mass or less.

[0018] Disintegrants are broadly classified into swelling type disintegrants and wicking type disintegrants. The swelling type disintegrant is insoluble in water, but takes in a larger amount of water than the voids in the disintegrant, and swells, destroying the tablet structure with its swelling force, and the water penetrates between the particles one after another, so the tablet is considered to disintegrate while being finely pulverized as if erupting. The wicking type disintegrant has a small contact angle, so the water infiltrates quickly, and the water penetrates into the tablet through the surface of the disintegrant, reducing the binding force between the particles, and the tablet is considered to disintegrate in a cracked shape. In the tablet of the present invention, since aminoalkyl methacrylate copolymer E is used, both swelling type disintegrants and wicking type disintegrants can be used, and are not particularly limited.

[0019] Examples of the swelling type disintegrants include croscarmellose sodium, carmellose calcium, crospovidone, low-substituted hydroxypropyl cellulose, sodium carboxymethyl starch, and hydroxypropyl starch. Of these, it is preferable to select from croscarmellose sodium, crospovidone, and low-substituted hydroxypropyl cellulose. Examples of the wicking type disintegrants include partially pregelatinized starch, carmellose, corn starch, and crystalline cellulose. These disintegrants may be used alone or in combination of two or more.

[0020] The content of the disintegrant in the tablet is not particularly limited, but is preferably 0.01% by mass or more, more preferably 0.1% by mass or more, based on the total mass of the tablet, and is preferably 30% by mass or less, more preferably 25% by mass or less, based on the total mass of the tablet.

[0021] The tablet of the present invention may contain, in addition to the active ingredients abiraterone acetate, disintegrant, and aminoalkyl methacrylate copolymer E, additives commonly used in this field, such as binders other than aminoalkyl methacrylate copolymer E, solubilizers, excipients, sweeteners, flavors, flow agents, lubricants, flavorings, colorants, and surfactants. The tablet of the present invention may also be a film-coated tablet. When the tablet of the present invention is a film-coated tablet, the tablet of the present invention may further contain, in addition to the above additives, a film-coating base for forming a film-coating layer.

[0022] The binder other than aminoalkyl methacrylate copolymer E that can be contained in the granules is not particularly limited, but includes hydroxypropyl cellulose, povidone, polyvinyl alcohol, hypromellose, methylcellulose, hydroxyethyl cellulose, gelatin, agar, sodium alginate, dextrin, xanthan gum, powdered gum arabic, partially saponified polyvinyl alcohol, and pullulan. Among them, at least one selected from the group consisting of hydroxypropyl cellulose, povidone, polyvinyl alcohol, and hypromellose is preferable, at least one selected from hydroxypropyl cellulose, povidone, and polyvinyl alcohol is more preferable, and hydroxypropyl cellulose is particularly preferable. These may be used alone or in combination of two or more.

[0023] When a binder other than aminoalkyl methacrylate copolymer E is used in combination, its content in the tablet is not particularly limited, but is preferably 0.01% by mass or more, more preferably 0.1% by mass or more. In addition, the content of the binder other than aminoalkyl methacrylate copolymer E in the tablet is preferably 20% by mass or less, more preferably 10% by mass or less.

[0024] The solubilizer is not particularly limited, but examples thereof include anionic surfactants such as sodium lauryl sulfate and dioctyl sodium sulfosuccinate, nonionic surfactants such as polyoxyethylene glycol sorbitan alkyl esters (e.g., polysorbate 80, etc.) and polyethylene glycols, and various other surfactants. Among them, anionic surfactants such as sodium lauryl sulfate are preferred, and sodium lauryl sulfate is more preferred, because they generally have a relatively high solubilizing ability and the active ingredient is a basic drug. The solubilizer may be used alone or in combination of two or more kinds.

[0025] When a solubilizer is used, its content in the tablet varies depending on the content of abiraterone acetate and binder in the tablet and is not particularly limited, but is usually preferably 0.1 to 10 mass%, more preferably 0.5 to 5 mass%, of the total mass of the tablet.

[0026] The excipient is not particularly limited, but examples thereof include celluloses (such as crystalline cellulose and ethyl cellulose) and derivatives thereof, sugars (such as glucose, lactose, sucrose, refined sucrose, powdered sugar, trehalose, dextran, dextrin, and hydrates thereof), sugar alcohols (such as D-mannitol, xylitol, sorbitol, erythritol), glycerin fatty acid esters, inorganic powders (magnesium aluminometasilicate, synthetic hydrotalcite), anhydrous calcium phosphate, precipitated calcium carbonate, calcium silicate, calcium hydrogen phosphate hydrate, and inorganic salts such as sodium hydrogen carbonate. Among these, celluloses such as crystalline cellulose and sugars such as lactose and lactose hydrate are preferred. The excipients may be used alone or in combination of two or more.

[0027] When an excipient is used, its content in the tablet varies depending on the content of abiraterone acetate and disintegrant in the tablet and is not particularly limited, but is preferably 0.1 to 30% by mass, more preferably 0.5 to 20% by mass, based on the total mass of the tablet.

[0028] The lubricant is not particularly limited, but examples thereof include stearic acid, sodium stearyl fumarate, magnesium stearate, calcium stearate, sucrose fatty acid ester, polyethylene glycol, hardened oil, glycerin fatty acid ester, talc, etc. Among them, magnesium stearate is preferred because of its high lubricity. These may be used alone or in combination of two or more.

[0029] When a lubricant is used, the content of the lubricant in the tablet is an amount that can prevent the above-mentioned abiraterone acetate and various additives from adhering to the equipment (punches and dies) used to manufacture the tablets. This amount varies depending on the type of lubricant used, so is not particularly limited, but typically, the content is preferably 0.1 to 10 mass%, more preferably 0.5 to 5 mass%, based on the total mass of the tablet.

[0030] The fluidizing agent is not particularly limited, but examples thereof include silicates such as calcium silicate, anhydrous silicic acid such as light anhydrous silicic acid, hydrous silicon dioxide, talc, titanium oxide, stearic acid, magnesium stearate, calcium stearate, magnesium aluminometasilicate, etc. These may be used alone or in combination of two or more.

[0031] When a flow agent is used, its content in the tablet should be an amount sufficient to allow the above-mentioned powder abiraterone acetate and various additives to flow smoothly during tablet production. This amount varies depending on the type of flow agent used, so is not particularly limited; however, it is usually preferably 0.1 to 10% by mass, more preferably 0.5 to 5% by mass, based on the total mass of the tablet.

[0032] The tablet of the present invention can be made into a film-coated tablet by applying a coating to the surface of the tablet using a film coating base, which is expected to have effects such as masking bitterness and unpleasant odors, improving the stability of the active ingredient against external conditions such as moisture, light and oxygen, improving the appearance and increasing the commercial value.

[0033] The film coating base is not particularly limited, and polymers such as hydroxypropyl cellulose, hypromellose, carmellose sodium, ethyl acrylate-methyl methacrylate copolymer dispersion, polyvinylpyrrolidone, polyvinyl alcohol, polyoxyethylene polyoxypropylene glycol, etc. Plasticizers such as polyethylene glycol, propylene glycol, triacetin, triethyl citrate, etc., colorants such as titanium oxide, ferric oxide, aluminum lake, etc., and gloss agents such as carnauba wax, etc. can be appropriately added to the film coating base as necessary.

[0034] When the tablet of the present invention is a film-coated tablet, the mass of the film-coating layer is not particularly limited as long as it is an amount sufficient to cover the entire tablet. However, in order to allow the abiraterone acetate in the tablet to be rapidly dissolved after ingestion, it is preferable that the mass of the part of the tablet other than the film-coating layer is 0.1 to 5 parts by mass, and more preferably 1 to 5 parts by mass, where the mass of the part of the tablet other than the film-coating layer is 100 parts by mass.

[0035] The tablet of the present invention is useful for treating castration-resistant prostate cancer and prostate cancer with high-risk prognostic factors that has not been treated with endocrine therapy.

[0036] The dosage of the tablet of the present invention is not particularly limited as long as it is within the scope of common knowledge in the art. For example, in the treatment of castration-resistant prostate cancer, the dosage is 500 mg to 1000 mg, particularly 1000 mg, calculated as abiraterone acetate per day for an adult, and the daily dosage can be taken in 1 to 4 divided doses.

[0037] (Tablet manufacturing method) The method for producing tablets can be a method generally used in the art, and is not particularly limited as long as it includes at least a step of mixing and granulating abiraterone acetate, a disintegrant, and aminoalkyl methacrylate copolymer E. For example, abiraterone acetate can be produced by mixing and granulating a specific additive including a disintegrant and aminoalkyl methacrylate copolymer E, mixing the obtained granule with other additives, and tableting. In this case, it is more preferable to include a solubilizer in the granule. The granulation method is not particularly limited, and granulation methods commonly used in the pharmaceutical field, such as dry granulation and wet granulation, can be used. The tableting method is not particularly limited, and for example, a method using a tableting mortar, an upper tableting punch, and a lower tableting punch, using a hydraulic hand press, a single punch tableting machine, a rotary tableting machine, etc., can be used. The tableting may be carried out at a tableting pressure such that the resulting tablets have an appropriate hardness, and the tableting pressure is appropriately adjusted depending on the tableting method, the equipment used for tableting, the size of the tablets, etc.

[0038] The shape of the obtained tablet is not particularly limited, and may be, for example, a disk, a doughnut, a polygonal plate, a sphere, an ellipse, a caplet, etc. The size is preferably small, and for example, in the case of an ellipse, the major axis is preferably about 8 to 15 mm, the minor axis is preferably about 5 to 12 mm, and the thickness is preferably about 3 to 8 mm. In addition, in the case of a circle, the diameter is preferably about 5 to 15 mm, and the thickness is preferably about 2.5 to 6 mm.

[0039] (Film coating method) The film coating method can be a method for producing a film-coated tablet that is generally used in the art. For example, tablets containing abiraterone acetate are loaded into a film coating machine, and a coating liquid in which the film coating agent and additives are dissolved or dispersed in an appropriate solvent such as water, an organic solvent such as ethanol, or a mixture thereof (e.g., a water / ethanol mixture) is sprayed onto the tablets, followed by drying.

[0040] The present invention will now be described in detail with reference to examples, but it is not intended that the present invention be limited to these examples. EXAMPLES

[0041] Details of the reagents used in the examples are given below. Abiraterone acetate Sodium lauryl sulfate: Japanese Pharmacopoeia XVII Aminoalkyl methacrylate copolymer E: Japanese Pharmacopoeia XVII EUDRAGIT (registered trademark) E PO manufactured by Evonik Hydroxypropyl cellulose (HPC) SL (number average molecular weight: 10 × 10 4 ):Japanese station XVII Hydroxypropyl cellulose (HPC) L (number average molecular weight: 14 × 10 4 ):Japanese station XVII Crospovidone: Japanese Pharmacopoeia XVII Low-substituted hydroxypropyl cellulose (L-HPC): Japanese Pharmacopoeia XVII Croscarmellose sodium: Japanese Pharmacopoeia XVII Partially pregelatinized starch: JP XVII PCS (registered trademark) manufactured by Asahi Kasei Corporation Magnesium stearate: Japanese Pharmacopoeia XVII Light anhydrous silicic acid: Japanese Pharmacopoeia XVII

[0042] In the above, JP XVII stands for the 17th Edition of the Japanese Pharmacopoeia.

[0043] Examples 1 to 5, Comparative Examples 1 and 2 According to the formulation in Table 1, abiraterone acetate, sodium lauryl sulfate, a binder, and a disintegrant were mixed in a mixer (V-type mixer (V-20), manufactured by Tokuju Machine Works, Ltd.). Water was added to the obtained mixed powder and further mixed to form a wet mass, which was dried at 60°C in a shelf dryer (DN43, manufactured by Yamato Scientific Co., Ltd.). This was granulated using a pestle and mortar to obtain a granulated product. According to the formulation in Table 1, magnesium stearate and light anhydrous silicic acid were added to the obtained granulated product and mixed in a mixer (V-type mixer (V-20), manufactured by Tokuju Machine Works, Ltd.), and the obtained mixture was placed in an electric press (N3043-00, manufactured by NPA System Co., Ltd.) and tableted with a tableting pressure of 12 kN, a major axis of 13.1 mm, a minor axis of 7.0 mm, and a thickness of 5 mm to obtain tablets with the masses shown in the table.

[0044] [Table 1]

[0045] Test Example 1: Dissolution characteristics test Tablets immediately after production in Examples 1 to 5 and Comparative Examples 1 and 2 were stored in an open environment at a temperature of 60°C and a humidity of 75% for 7 days. The start of storage was set as day 0, and for each tablet on the 3rd or 7th day after the start of storage, a dissolution test was performed according to the Japanese Pharmacopoeia dissolution test method by the paddle method using the Japanese Pharmacopoeia dissolution test first fluid (pH 1.2) as the dissolution test fluid in a dissolution tester (product name: NTR-6000 series, manufactured by Toyama Sangyo Co., Ltd.). The test conditions were a volume of 900 mL of dissolution medium, a temperature of 37±0.5°C, and a paddle speed of 75 rpm. The results are shown in average values ​​in Figures 1 to 7 and Table 2.

[0046] [Table 2]

[0047] From Figures 1 and 2 and Table 2, it can be seen that the tablet of Example 1 using aminoalkyl methacrylate copolymer E as a binder shows good dissolution characteristics even after storage under harsh conditions, compared to the tablet of Comparative Example 1 using HPC as a binder without containing aminoalkyl methacrylate copolymer E. Also, from Figures 3 and 4 and Table 2, it can be seen that the tablet of Example 2 using a combination of aminoalkyl methacrylate copolymer E and HPC as a binder has significantly improved the decrease in dissolution characteristics after storage under harsh conditions, compared to Comparative Example 2 using only HPC as a binder. Furthermore, from Figures 1, 5 to 7 and Table 2, it can be seen that when aminoalkyl methacrylate copolymer E is used as a binder, good dissolution characteristics are shown even after storage under harsh conditions, even if the type of disintegrant is changed in various ways. The dissolution characteristics after storage under harsh conditions in Examples 1 to 5 were equivalent to those of commercially available Zytiga (registered trademark) tablets 250 mg.

Claims

1. A tablet comprising a granule containing 55 to 95% by mass of abiraterone acetate as an active ingredient based on the total mass of the tablet, a disintegrant, and aminoalkyl methacrylate copolymer E.

2. 2. The tablet according to claim 1, wherein the total mass of the tablet is 420 mg or less.

3. The tablet according to claim 1 or 2, wherein the tablet contains 65 to 95% by mass of abiraterone acetate based on the total mass of the tablet.

4. The tablet according to any one of claims 1 to 3, wherein the disintegrant is at least one selected from the group consisting of croscarmellose sodium, crospovidone, low-substituted hydroxypropyl cellulose, and partially pregelatinized starch.

5. The tablet according to any one of claims 1 to 4, further comprising a further binder.

Citation Information

Patent Citations

  • Ibuprofen-containing solid preparation

    JP2011132219A

  • Solid pharmaceutical composition and pharmaceutical preparation

    JP2011201876A

  • Solid pharmaceutical composition and pharmaceutical preparation

    JP2012184171A

  • Abiraterone acetate formulation

    JP2018135351A

  • Tablets and method for producing same

    WO2019151405A1